Browsing by Author "Yilmaz F."
Now showing 1 - 9 of 9
Results Per Page
Sort Options
Item Bile duct response to repeated cerulein induced pancreatitis in the rat(2002) Menteş A.; Aydede H.; Bayol Ü.; Yilmaz F.The typical morphology of common bile duct strictures in chronic pancreatitis suggests a pathogenesis not of encasement, but of mural changes in the common bile duct. Cerulein, 20 μg/kg was administered to male Wistar rats in four subcutaneous doses, hourly for 3 h, and was recorded as one application. Group A served as controls and received subcutaneous saline. Group B1 received one application of Cerulein and was sacrificed after 24 h. Group B2 was similar to B1, but was sacrificed two weeks later. Group B3 was given two applications of Cerulein with an interval of two weeks and was sacrificed two weeks after the second application. Group B4 received one application of Cerulein every week for four weeks and was sacrificed two weeks after the last application. Serum amylase levels, pancreatic edema and peripancreatic inflammatory infiltration scores increased with the severity and persistance of the insult. Bilirubin and alkaline phosphatase levels suggested cholestatic response in the groups that received repeated insults with Cerulein (Groups B3 and B4: p < 0.01). Moderate to strong immuno-histochemical positivity for type IV collagen at the wall of the common bile duct in animals with a persisting insult is suggestive of circumstantial evidence for mural changes as a causative factor of stricture formation in similar settings such as chronic pancreatitis with persistent inflammatory attacks.Item 99mTc-Doxycycline hyclate: A new radiolabeled antibiotic for bacterial infection imaging(John Wiley and Sons Ltd, 2014) Ilem-Özdemir D.; Asikoglu M.; Ozkilic H.; Yilmaz F.; Hosgor-Limoncu M.; Ayhan S.Radiolabeled antibiotics are promising radiopharmaceuticals for the precise diagnosis and detection of infectious lesions. Doxycycline Hyclate (DOX) was chosen to investigate new 99mTc-labeled antibacterial agent. Ready to use freeze dry kits were formulated with optimum labeling conditions. Human serum stability, sterility, and pyrogenicity of kits were estimated, and gamma scintigraphy, in vivo biodistribution, and histopathological studies with bacterial infected rats were performed. DOX were successfully labeled by 99mTc with high radiochemical purity, and the labeled compound was stable in human serum. Kits were sterile, pyrogen-free, and stable up to 6 months. Static images depicted rapid distribution throughout the body and high uptake in bacterial infected thigh muscle. The uptake ratios of radiopharmaceuticals in infected thigh muscle were found above 2 up to 5 h. Five hours after injection, the rats were sacrificed, and biodistribution was determined. Samples of bacterial infected muscle, healthy muscle, blood, liver, spleen, lung, kidney, stomach, intestine, urine and heart were weighed, and the radioactivity was measured by using a gamma counter. The %ID/g of 99mTc-DOX was found 0.23 ± 0.06 for infected thigh muscle. According to the imaging, biodistribution, and histopathological studies, the promising characteristics of 99mTc-DOX make the new radiopharmaceutical valuable to examine for future studies. Copyright © 2013 John Wiley & Sons, Ltd.Item Gamma scintigraphy and biodistribution of 99mTc-cefotaxime sodium in preclinical models of bacterial infection and sterile inflammation(John Wiley and Sons Ltd, 2016) Ilem-Ozdemir D.; Asikoglu M.; Ozkilic H.; Yilmaz F.; Hosgor-Limoncu M.; Ayhan S.99mTc-cefotaxime sodium (99mTc-CEF) was developed and standardized under varying conditions of reducing and antioxidant agent concentration, pH, radioactivity dose, and reducing agent type. Labeling studies were performed by changing the selected parameters one by one, and optimum labeling conditions were determined. After observing the conditions for maximum labeling efficiency and stability, lyophilized freeze dry kits were prepared accordingly. Simple method for radiolabeling of CEF with 99mTc has been developed and standardized. Labeling efficiency of 99mTc-CEF was assessed by both radio thin-layer chromatography and radio high-performance liquid chromatography and found higher than 90%. The labeled compound was found to be stable in saline and human serum up to 24 h. Two different freeze dry kits were developed and evaluated. Based on the data obtained from this study, both products were stable for 6 months with high labeling efficiency. The prepared cold kit was found sterile and pyrogen free. The bacterial infection and sterile inflammation imaging capacity of 99mTc-CEF was evaluated. Based on the in vivo studies, 99mTc-CEF has higher uptake in infected and inflamed thigh muscle than healthy thigh muscle. Cefotaxime sodium (CEF) was successfully labeled with 99mTc from newly developed instant kit. Radiochemical purity was found greater than 90% and the labeled compound was stable in human serum during incubation period up to 24 h. The improved kit was found to be sterile, pyrogen free and stable up to 6 months. According to gamma scintigraphy studies, 99mTc-CEF showed a higher uptake in bacterial infected and sterile inflamed muscle than healthy thigh muscle. © Copyright 2016 John Wiley & Sons, Ltd.Item Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in turkey(Turkiye Klinikleri, 2021) Soyer N.; Ali R.; Turgut M.; Haznedaroğlu İ.C.; Yilmaz F.; Aydoğdu İ.; Pir A.; Karakuş V.; Özgür G.; Kiş C.; Ceran F.; Ilhan G.; Özkan M.; Aslaner M.; Ince İ.; Yavaşoğlu İ.; Gediz F.; Sönmez M.; Güvenç B.; Özet G.; Kaya E.; Vural F.; Şahin F.; Töbü M.; Durusoy R.; Saydam G.Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment. © TÜBİTAK.Item The impact of the informed consent process on the anxiety levels of patients undergoing rhinoplasty(Lippincott Williams and Wilkins, 2022) Aysel A.; Uz U.; Karatan B.; Aydin E.; Erdogˇan E.; Yilmaz F.; Müderris T.Septorhinoplasty is one of the most common elective surgical procedures in otolaryngology. The present study aimed to evaluate the anxiety levels of patients who underwent septorhinoplasty at different times, compare the information methods, and determine the understanding of the informed consent through recall rates of the complications explained in the informed consent process. The patients were divided into the following 2 groups: Group 1 (giving information 14 days before the surgery) and Group 2 (giving information 3 days before the surgery). For the preoperative anxiety measurement, the State anxiety scale of the State-Trait Anxiety Inventory (STAI) was used. All patients were asked to recall the complications they remembered from the consent form on the day before the surgery. Each group has consisted of 25 patients. No significant difference was found between the STAI-1 and STAI-2a anxiety scores between groups. In Group 1, the STAI-2b anxiety score was significantly lower than the STAI-1 and STAI-2a scores (P < 0.05). In Group 2, the mean score of STAI-2b was not significantly higher than the STAI-1 and STAI-2 scores (P > 0.05). When the STAI-2b scores of the two groups were compared, the scores of Group 2 were significantly higher (P < 0.05). The most commonly remembered complications were bruising and swelling in both of the groups. In conclusion, the authors believe that long-term cooperation between the surgical team and the patient will reduce the anxiety levels of the patients and increase patients’ satisfaction, resulting in a significant reduction in the amount of potential legal processes. Copyright © 2021 by Mutaz B. Habal, MD.Item The clinicopathological features and survival of Castleman disease: A multicenter Turkish study(Verduci Editore s.r.l, 2022) Yildiz J.; Bagci M.; Sayin S.; Kaya A.; Yilmaz F.; Ekinci O.; Dal M.S.; Basturk A.; Aydogdu I.; Albayrak M.; Dogan A.; Erkurt M.A.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.Item Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer(Newlands Press Ltd, 2023) Kahraman S.; Erul E.; Seyyar M.; Gumusay O.; Bayram E.; Demirel B.C.; Acar O.; Aksoy S.; Baytemur N.K.; Sahin E.; Cabuk D.; Basaran G.; Paydas S.; Yaren A.; Guven D.C.; Erdogan A.P.; Demirci U.; Yasar A.; Bayoglu İ.V.; Hizal M.; Gulbagci B.; Paksoy N.; Davarci S.E.; Yilmaz F.; Dogan O.; Orhan S.O.; Kayikcioglu E.; Aytac A.; Keskinkilic M.; Mocan E.E.; Unal O.U.; Aydin E.; Yucel H.; Isik D.; Eren O.; Uluc B.O.; Ozcelik M.; Hacibekiroglu I.; Aydiner A.; Demir H.; Oksuzoglu B.; Cilbir E.; Cubukcu E.; Cetin B.; Oktay E.; Erol C.; Okutur S.K.; Yildirim N.; Alkan A.; Selcukbiricik F.; Aksoy A.; Karakas Y.; Ozkanli G.; Duman B.B.; Aydin D.; Dulgar O.; Er M.M.; Teker F.; Yavuzsen T.; Aykan M.B.; Inal A.; Iriagac Y.; Kalkan N.O.; Keser M.; Sakalar T.; Menekse S.; Kut E.; Bilgin B.; Karaoglanoglu M.; Sunar V.; Ozdemir O.; Turhal N.S.; Karadurmus N.; Yalcin B.; Nahit Sendur M.A.Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.Item Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study(BioMed Central Ltd, 2024) Kahraman S.; Hizal M.; Demirel B.C.; Guven D.C.; Gumusay O.; Uluc B.O.; Bayram E.; Gulbagci B.; Yasar A.; Davarci S.E.; Mocan E.E.; Acar O.; Isik D.; Aydin E.; Karakas Y.; Ozcelik M.; Keser M.; Okutur S.K.; Eren O.; Menekse S.; Aydin D.; Yilmaz F.; Dogan O.; Ozkanli G.; Yucel H.; Sunar V.; Aykan M.B.; Ozdemir O.; Duman B.B.; Keskinkilic M.; Sakalar T.; Inal A.; Karaoglanoglu M.; Aksoy A.; Er M.M.; Turhal N.S.; Kalkan N.O.; Sendur M.A.N.Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65–69 years old, 70–79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3–22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9–54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3–4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC. © The Author(s) 2024.Item Synthesis and Anticancer Activities of Amide-Bridged Coumarin–Quinazolinone Hybrid Compounds(Pleiades Publishing, 2024) Çalişkan N.; Menteşe E.; Yilmaz F.; Ilhan M.S.Abstract: Some novel 3-aminoquinazolin-4(3H)-one derivatives were synthesized by the reaction of 2-aminobenzhydrazide and corresponding iminoester hydrochlorides and then reacted with coumarin-3-carbonyl chloride to obtain novel coumarin–quinazolinone hybrids. The synthesized hybrid compounds were screened for their anticancer activity against various human cancer and normal cell lines. N-{2-[(4-Bromo- and N-{2-[(3-bromo-phenyl)methyl]-4-oxoquinazolin-3(4H)-yl}-2-oxo-2H-1-benzopyran-3-carboxamides exhibited the highest cytotoxic effect on the PC-3 prostate cancer cell line: IC50 35.3 ± 0.6 and 36.8 ± 0.8 µg/L, respectively. N-{2-[(4-Fluoro-, N-{2-[(4-bromo-, and N-{2-[(3,4-dichloro-phenyl)methyl]-4-oxoquinazolin-3(4H)-yl}-2-oxo-2H-1-benzopyran-3-carboxamides showed the highest activity against the MCF-7 breast cancer cell line: IC50 48.5 ± 0.4, 44.8 ± 0.4 and 46.1 ± 0.5 µg/L, respectively. © Pleiades Publishing, Ltd. 2024.